Red Light Holland (TRIP) Q1 2027 earnings summary

Executive summary

• Completed acquisition of Filament Health Corp. in Q1 2027, transforming the business into a focused life sciences platform centered on naturally derived psychedelic medicines.

• Strategic shift to pharmaceutical R&D, GMP manufacturing, regulatory, and clinical supply capabilities, with a focus on psilocybin (PEX010) and ibogaine (IBEX011) drug candidates.

• Emphasis on leveraging Filament’s expertise to expand regulated clinical and research supply opportunities and develop additional botanical drug candidates.

Financial highlights

• Revenue was $0.186M in Q1 2027, down from $0.553M in Q1 2026.

• Gross profit increased to $0.170M in Q1 2027 from $0.151M in Q1 2026.

• Net loss widened to $1.889M in Q1 2027 from $1.046M in Q1 2026.

• Adjusted EBITDA loss was $1.063M in Q1 2027 versus $0.679M in Q1 2026.

• Cash and cash equivalents stood at $2.598M, with $5.017M in short-term investments as of June 30, 2026.

Outlook and guidance

• Plans to advance PEX010 clinical and research supply programs and deepen relationships with academic and clinical institutions.

• Intends to leverage pharmaceutical capabilities and IP to pursue additional naturally derived drug candidates and commercial opportunities.

• Focus on disciplined capital allocation and execution to drive long-term value creation.